President Donald Trump has nominated Dr. Heidi Overton to serve as FDA commissioner, setting the stage for a Senate confirmation battle over abortion drug access. Overton, currently Trump's deputy assistant for domestic policy, is known for her pro-life views and could bring renewed scrutiny to mifepristone, the abortion pill used in more than two-thirds of U.S. abortions.
John Mize, chief executive of Americans United for Life, praised the nomination. Mize told Fox News Digital he has held multiple conversations with Overton and expressed optimism she would bring "objectivity to the issue of mifepristone in a way that will expose this drug for the damage it causes women."
Overton, a physician with experience in government and clinical medicine, previously directed the Center for a Healthy America at the Trump-aligned America First Policy Institute during the Biden administration. Her nomination was announced Aug. 10, 2026.
Mifepristone currently carries an FDA boxed warning—the agency's strongest safety alert—due to risks of serious and sometimes fatal infections or bleeding. The drug is approved for use up to 10 weeks of pregnancy.
The FDA stopped enforcing an in-person dispensing requirement for mifepristone in 2021 during the COVID-19 pandemic and later permanently removed this requirement following a review of safety data. Under current rules, patients can receive prescriptions after a telehealth visit, with the medication then mailed by a certified pharmacy. Pro-life activists have called for these rules to be tightened.
Overton's nomination follows a recent case in North Carolina where an 18-year-old woman was accused of using mifepristone and misoprostol to terminate a pregnancy at 31 weeks, well beyond the FDA's approved limit.
The anti-abortion movement has largely applauded Overton's nomination. Her confirmation fight will align with a broader federal safety review of mifepristone already underway. Senator Josh Hawley has also introduced legislation to strip FDA approval from the abortion pill.
